Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF.

Authors:
Sumit Middha, PhD
Sumit Middha, PhD
MSKCC
Principal Computational Biologist
next-gen sequencing NGS, bioinformatics, genomics
United States

Mol Cancer Res 2016 Mar 11;14(3):296-301. Epub 2015 Dec 11.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Unlabelled: Targeted therapy for metastatic colorectal carcinoma consists of anti-EGFR therapy for patients with RAS/RAF wild-type tumors. However, the response rate remains low, suggesting the presence of alternative drivers possibly also representing potential therapeutic targets. We investigated receptor tyrosine kinase (RTK) alterations and MAP2K1 (MEK1) mutations in a large cohort of colorectal carcinoma patients studied by Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets and The Cancer Genome Atlas, focusing on amplifications, fusions, and hotspot mutations in RTK genes and MAP2K1. RTK gene amplifications were confirmed with FISH and immunohistochemical (IHC) staining. Among 751 colorectal carcinoma cases with next-generation sequencing data, 7% and 1% of colorectal carcinoma harbored RTK alterations and MAP2K1 hotspot mutations (n = 7), respectively. RTK-altered cases had fewer concurrent RAS/RAF mutations (P = 0.003) than RTK/MAP2K1 wild-type colorectal carcinoma. MAP2K1-mutated colorectal carcinoma showed no RAS/RAF mutations. ERBB2 (n = 32) and EGFR (n = 13) were the most frequently altered RTKs, both activated by amplification and/or hotspot mutations. Three RTK fusions were identified: NCOA4-RET, ERBB2-GRB7, and ETV6-NTRK3. Only 1 of 6 patients with an RTK or MAP2K1 alteration who received anti-EGFR and/or anti-ERBB2 therapy demonstrated stable disease; the rest progressed immediately. Overall, RTK alterations and MAP2K1 mutations occur in approximately 8% of colorectal carcinoma. In spite of the usual absence of RAS/RAF mutations, response to anti-EGFR and/or anti-ERBB2 therapy was poor in this limited group. Larger studies are warranted to further define these kinase alterations as novel therapeutic targets in colorectal carcinoma and as negative predictors of response to anti-EGFR therapy.

Implications: Targetable kinase alterations were identified in a subset of advanced colorectal carcinoma patients, preferentially associated with wild-type RAS/RAF, and may predict poor response to standard anti-EGFR therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-15-0392-TDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972456PMC
March 2016
39 Reads
10 Citations
4.380 Impact Factor

Publication Analysis

Top Keywords

colorectal carcinoma
40
rtk alterations
12
ras/raf mutations
12
hotspot mutations
12
kinase alterations
12
alterations map2k1
12
colorectal
10
carcinoma
10
anti-egfr therapy
8
and/or anti-erbb2
8
wild-type ras/raf
8
anti-egfr and/or
8
therapeutic targets
8
mutations
8
anti-erbb2 therapy
8
associated wild-type
8
carcinoma patients
8
targetable kinase
8
response anti-egfr
8
preferentially associated
8

Similar Publications